Physician profile
Chad A Quist
NPI 1609836444
$40,138.40
in general payments reported to CMS, 2019-2025
19 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what 92% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,875 · 2022: $15K · 2023: $7,480 · 2024: $8,268 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $3,152 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,567.50 |
| Food and Beverage | $3,151.93 |
| Education | $284.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36,249.01 | 2021-2025 | |
| Allergan, INC. | $813.21 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $663.90 | 2021-2025 | Austedo Xr, Austedo |
| Livanova USA, INC. | $656.13 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy, Vns Therapy Symmetry Model 8103 Generator |
| Sk Life Science, INC. | $432.35 | 2021-2025 | Xcopri |
| Ucb, INC. | $250.64 | 2021-2025 | Briviact, Nayzilam |
| Lilly USA, LLC | $231.71 | 2021-2024 | Emgality, Reyvow |
| Lundbeck LLC | $142.30 | 2023-2025 | Vyepti |
| Axsome Therapeutics, INC. | $119.82 | 2025 | Symbravo |
| Pfizer INC. | $91.19 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $90.78 | 2023 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $81.53 | 2022 | |
| Novartis Pharmaceuticals Corporation | $74.66 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $70.33 | 2025 | |
| Neurelis, INC. | $64.42 | 2025 | Valtoco |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.85 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $29.53 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $24.65 | 2021 | |
| Novo Nordisk INC | $21.39 | 2024 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Quist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.